Accessibility Menu
Foghorn Therapeutics logo

Foghorn Therapeutics(NASDAQ) FHTX

Market Cap$278.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-74%
5 Year-48%
1 Year-13%
1 Month-3%
$4.55
-4.11%
-0.20Today
After hours$4.54-$0.01 (-0.15%)
Foghorn Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.742026-07-30
Foghorn Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.51%USD 5.072026-07-23
1 month-2.87%USD 4.882026-06-30
3 month-0.42%USD 4.762026-05-01
Year to date-12.22%USD 5.402025-12-31
1 year-13.03%USD 5.452025-07-30
3 year-48.25%USD 9.162023-07-31
5 year-47.74%USD 9.072021-07-30
Since inception-73.84%USD 18.122020-10-23

Foghorn Therapeutics Financials at a Glance

Market Cap

$278.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$28.22M

Net Income (TTM)

-$75.32M

EPS (TTM)

-$1.20

P/E Ratio

-3.94

Dividend

$0.00

Beta (Volatility)

1.62 (High)

Price

$4.55

Volume

157,610.997

Open

$4.74

Previous Close

$4.53

Daily Range

$4.41 - $4.95

52-Week Range

$3.27 - $6.95

Estimated Earnings Date

Aug 4, 2026

FHTX News

A medical professional using a microscope

Why Foghorn Therapeutics Blasted 55% Higher Today

Eric VolkmanDec 13, 2021

FHTX: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Foghorn Therapeutics

Foghorn helps people fighting cancer by creating new types of medicine. These drugs fix how cells turn genes on and off to stop tumors. This helps doctors treat serious diseases using the body's own genetic instructions.

What Is Foghorn Building?

  • FHD-909: A drug candidate in Phase 1 clinical trials for advanced cancers; developed through a partnership with Eli Lilly.
  • Gene Traffic Control: A proprietary platform used to study how the body regulates gene expression to find new drug targets.
  • Protein Degraders: Medicines designed to break down specific proteins that help cancer cells survive and grow.
  • Enzymatic Inhibitors: Small molecules that block the activity of specific enzymes involved in tumor development.

Partnerships and Progress

  • Partnered with Eli Lilly and Company in December 2021 to co-develop and commercialize new oncology medicines.
  • Entered a research agreement with Merck Sharp & Dohme Corp. to discover novel therapeutics against specific cancer targets.
  • Raised $49.7 million in net proceeds through a direct stock and warrant offering in January 2026.
  • Transitioned the FHD-909 program to Eli Lilly in late 2023 to begin shared development cost funding.

Controlling the Genetic Traffic

Foghorn specializes in the chromatin regulatory system, which acts as the "traffic control" for gene expression in cells. This system is involved in roughly 50% of all cancers, giving the company a broad range of potential treatment areas.

Recent Financial Facts

  • Collaboration revenue was $3.3 million in Q1 2026, down 45.1% from $6 million in Q1 2025.
  • Operating loss narrowed to $21.6 million in Q1 2026, a 5.8% improvement from $22.9 million in Q1 2025.
  • Net loss reached $19.9 million in Q1 2026, worsening by 5.5% compared to $18.8 million in Q1 2025.
  • Cash and marketable securities totaled $183.6 million as of March 31, 2026, boosted by a recent capital raise.

Bottom Line

Foghorn has evolved into a clinical-stage biotechnology firm with significant backing from major global pharmaceutical partners. Its unique focus on genetic regulation provides a distinct path for developing precision medicines for difficult-to-treat cancers.

AI Generated • May 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

106

CEO

Adrian Gottschalk, MBA

Website

www.foghorntx.com

Headquarters

Watertown, MA 02472, US

FHTX Financials

Key Financial Metrics (TTM)

Gross Margin

22.26%

Operating Margin

-286.16%

Net Income Margin

-266.88%

Return on Equity

85.78%

Return on Capital

N/A

Return on Assets

-33.90%

Earnings Yield

-25.38%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$278.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

58.71M

Volume

157.61K

Avg. Volume

246.26K

Financials (TTM)

Gross Profit

$6.28M

Operating Income

-$80.77M

EBITDA

-$72.53M

Operating Cash Flow

-$87.40M

Capital Expenditure

-$22.00K

Free Cash Flow

-$87.42M

Cash & ST Invst.

$184.88M

Total Debt

$41.99M

Foghorn Therapeutics Performance Analysis

Foghorn Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 19,228,0001357.8%
20232023-12-31USD 34,155,00077.6%
20242024-12-31USD 22,602,000-33.8%
20252025-12-31USD 30,909,00036.8%
Foghorn Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3027.0%
Q32025-09-307.9%
Q42025-12-3113.4%
Q12026-03-31-64.7%
Foghorn Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.62-4.0%
20232023-12-31USD -2.34-10.4%
20242024-12-31USD -1.58-32.7%
20252025-12-31USD -1.18-25.2%
Foghorn Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-306.7%
Q32025-09-3010.7%
Q42025-12-31-40.0%
Q12026-03-3117.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$3.27M

-45.1%

Gross Profit

$3.03M

-49.1%

Gross Margin

92.72%

N/A

Market Cap

$278.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.63M

N/A

Employees

106

N/A

Net Income

-$19.88M

-5.5%

EBITDA

-$19.64M

-9.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$184.88M

-16.2%

Total Debt

$41.99M

+20.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$40.13M

+55.9%

Short Term Debt

$1.86M

-79.6%

Return on Assets

-33.90%

N/A

Return on Invested Capital

-51.20%

N/A

Free Cash Flow

-$25.27M

-5.3%

Operating Cash Flow

-$25.27M

-5.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRDAEntrada Therapeutics, Inc.
$6.79+0.30%
VNDAVanda Pharmaceuticals Inc.
$5.10-1.54%
SGMTSagimet Biosciences Inc.
$7.11-2.74%
ENTAEnanta Pharmaceuticals, Inc.
$12.60-3.08%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About FHTX

What is the current price of Foghorn Therapeutics?

Foghorn Therapeutics is trading at $4.53 per share.

What is the 52-week range for Foghorn Therapeutics?

Over the past 52 weeks, Foghorn Therapeutics has traded between $3.27 and $6.95.

How much debt does Foghorn Therapeutics have?

As of the most recent reporting period, Foghorn Therapeutics reported total debt of $41.99M.

How much cash does Foghorn Therapeutics have on hand?

Foghorn Therapeutics reported $88.91M in cash and cash equivalents in its most recent financial results.

What is Foghorn Therapeutics’s dividend yield?

Foghorn Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services